Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $5.70 as of June 8th.
Tonhom1009/Shutterstock.com
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. WVE is presented as a clinical-stage RNA editing company advancing its WVE-006 program in alpha-1 antitrypsin deficiency (AATD), with recent ATS data strengthening the platform validation thesis.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The 400 mg monthly and 200 mg biweekly cohorts achieved M-AAT levels within the natural MZ heterozygote band, with total AAT reaching up to 13.6 µM and sustained Z-AAT reductions approaching ~70%, reinforcing a clear dose-response relationship. Dynamic acute-phase responses observed during infections showed correlated CRP and AAT elevations, previously seen as a single case but now reproduced across multiple patients, suggesting preserved physiological responsiveness absent in standard IV augmentation therapy.
Safety remained clean across single and multidose regimens, with no serious adverse events or liver enzyme signals reported. Durable editing effects lasting at least three months and a favorable convenience profile support potential monthly dosing as a commercially viable regimen. The dataset materially de-risks the accelerated approval pathway ahead of mid-2026 FDA feedback and strengthens the hepatology readout expected at EASL.
Despite a recent stock decline from $7.05 to $6.40, the market appears to be pricing in uncertainty ahead of data rather than fundamentals. Overall, Wave Life Sciences emerges as a clinically validated RNA editing platform with meaningful upside optionality tied to regulatory and pipeline expansion catalysts.
This positions the company for a potential significant rerating as investors reassess its probability-weighted pipeline value, with additional upside optionality from future indications including obesity, while the current market valuation continues to lag improving clinical evidence and expanding proof of concept trajectory.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy, gene editing commercialization, pipeline optionality, and ~$132 upside potential. CRSP’s stock price has appreciated by approximately 25.94% since our coverage. Biotech Distilled shares a similar view but emphasizes RNA editing platform validation in Wave Life Sciences (WVE) with stronger near-term clinical de-risking and regulatory catalyst visibility.
Wave Life Sciences Ltd. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held WVE at the end of the first quarter which was 45 in the previous quarter. While we acknowledge the risk and potential of WVE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WVE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
